scholarly journals Visual Function and Disability Are Associated With Focal Thickness Reduction of the Ganglion Cell-Inner Plexiform Layer in Patients With Multiple Sclerosis

2019 ◽  
Vol 60 (4) ◽  
pp. 1213 ◽  
Author(s):  
Ce Shi ◽  
Hong Jiang ◽  
Giovana Rosa Gameiro ◽  
Huiling Hu ◽  
Jeffrey Hernandez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Ganglion Cell ◽  
Visual Function ◽  
Plexiform Layer ◽  
Thickness Reduction ◽  
Inner Plexiform Layer

scholarly journals The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients

2017 ◽  
Vol 25 (1) ◽  
pp. 31-38 ◽  
Author(s):  
Anna M Pietroboni ◽  
Laura Dell’Arti ◽  
Michela Caprioli ◽  
Marta Scarioni ◽  
Tiziana Carandini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Ganglion Cell ◽  
Ganglion Cells ◽  
Gray Matter Volume ◽  
Brain Magnetic Resonance Imaging ◽  
Plexiform Layer ◽  
Inner Plexiform Layer ◽  
Fiber Layer ◽  
Cortical Regions ◽  
Multiple Sclerosis Patients

Background: The importance of neurodegeneration in multiple sclerosis (MS) is increasingly well recognized. Objectives: To evaluate retinal pathology using optical coherence tomography (OCT) and to investigate possible associations between retinal layers’ thickness and specific patterns of gray matter volume in patients with a new diagnosis of MS. Methods: A total of 31 patients underwent OCT scans and brain magnetic resonance imaging. In total, 30 controls underwent the same OCT procedure. The association between focal cortical volume and OCT measurements was investigated with voxel-based morphometry (VBM). Results: Compared to controls, patients’ macular retinal nerve fiber layer (mRNFL), macular ganglion cell layer (mGCL), macular inner plexiform layer (mIPL), and macular ganglion cell-inner plexiform layer (mGCIPL) thickness were significantly reduced ( p = 0.0009, p = 0.0003, p = 0.0049, and p = 0.0007, respectively). Peripapillary RNFL (pRNFL) and temporal sector pRNFL (T-pRNFL) did not show any significant changes, although there was a trend toward T-pRNFL thinning ( p = 0.0254). VBM analysis showed that mGCIPL and pRNFL were significantly correlated with the volume reduction of occipital-parietal cortex ( p < 0.005). Conclusion: mRNFL, mGCL, and mIPL are significantly reduced in MS patients without concomitant pRNFL thinning. These retinal changes show a significant association with cortical regions that are known to be important for visuospatial performance.

Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis

Neurology ◽  
2021 ◽  
pp. 10.1212/WNL.0000000000011933
Author(s):  
Jeffrey Lambe ◽  
Hunter Risher ◽  
Angeliki G. Filippatou ◽  
Olwen C. Murphy ◽  
Elias S. Sotirchos ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Ganglion Cell ◽  
Plexiform Layer ◽  
Rate Of Change ◽  
Uncontrolled Hypertension ◽  
Inner Plexiform Layer ◽  
Disease Modifying Therapy ◽  
Retinal Atrophy ◽  
The Difference

Objective:To investigate the effects of rituximab on retinal atrophy in patients with relapsing-remitting multiple sclerosis (RRMS), we performed serial optical coherence tomography (OCT) scans among a cohort of RRMS patients on rituximab, and compared rates of ganglion cell+inner plexiform layer (GCIPL) atrophy to those observed among age- and sex-matched glatiramer acetate (GA)- and natalizumab-treated RRMS patients, and healthy controls (HCs).Methods:In this observational study, patients with RRMS treated with a single disease-modifying therapy, and HCs, were followed with serial OCT for a median duration of 2.8 years. Participants with uncontrolled hypertension, diabetes mellitus, or glaucoma, and eyes with optic neuritis ≤6 months prior to baseline OCT, or during follow-up, were excluded. Statistical analyses were performed using linear mixed-effects regression.Results:During the overall follow-up period, rates of GCIPL atrophy were -0.28±0.11µm/yr among rituximab-treated RRMS patients (n=35). This was similar to GA-treated (n=49; -0.33±0.05µm/yr; p=0.69) and natalizumab-treated patients (n=88; -0.17±0.10µm/yr; p=0.13), and faster than HCs (n=78; -0.15±0.03µm/yr; p=0.006). Rituximab-treated patients exhibited 0.55±0.23µm/yr faster rates of GCIPL atrophy during the first 12 months of treatment, relative to afterwards (n=25; p=0.02), during which period GCIPL atrophy rates were -0.14±0.13µm/yr.Conclusions:Retinal atrophy in RRMS is modulated by rituximab. Greater attenuation of retinal atrophy may occur after 12 months of rituximab treatment, following which time GCIPL atrophy rates are similar to those observed among natalizumab-treated RRMS patients and HCs. Our findings raise the possibility that the neuroprotective therapeutic response with rituximab in RRMS may take up to 12 months, though should be confirmed by larger studies.Classification of evidence:This study provides Class IV evidence on the difference in rate of change of the ganglion cell+inner plexiform layer thickness in patients with RRMS, comparing rituximab to other DMTs.

Sign in / Sign up

Export Citation Format

Share Document